Sildenafil citrate does not affect QT intervals and QT dispersion: An important observation for drug safety

Annals of Noninvasive Electrocardiology

Volumn 8, Issue 1, 2003, Pages 14-17

  Alpaslan, Mete ^a,b   Onrat, Ersel ^a   Samli, Murat ^a   Dincel, Cetin ^a  

^a AFYON KOCATEPE UNIVERSITY   (Turkey)

^b SELCUK UNIVERSITY   (Turkey)

Author keywords

Electrocardiography; QT dispersion; Sildenafil citrate

Indexed keywords

SILDENAFIL; CYCLIC GMP PHOSPHODIESTERASE; PIPERAZINE DERIVATIVE;

ADULT; ARTICLE; CORONARY ARTERY DISEASE; DIABETES MELLITUS; DRUG SAFETY; ELECTROCARDIOGRAM; ERECTILE DYSFUNCTION; HEART RATE; HEART VENTRICLE ARRHYTHMIA; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; QT DISPERSION; QT INTERVAL; SIDE EFFECT; AGED; DRUG EFFECT; ELECTROCARDIOGRAPHY; HEART MUSCLE CONDUCTION SYSTEM; MIDDLE AGED;

3',5'-CYCLIC-GMP PHOSPHODIESTERASE; ADULT; AGED; ELECTROCARDIOGRAPHY; HEART CONDUCTION SYSTEM; HEART RATE; HUMANS; MALE; MIDDLE AGED; PIPERAZINES;

EID: 1842475108     PISSN: 1082720X     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1542-474X.2003.08103.x     Document Type: Article

References (24)

1. Kloner RA. Erectile dysfunction and cardiovascular risk factors. Hosp Pract 2001;36:41-4, 49-51.
2. Kloner RA. Hypertension as a risk for erectile dysfunction: Implications for sildenafil use. J Clin Hypertens 2000;2:33-36.
3. Manecke RG, Mulhall JP. Medical treatment of erectile dysfunction. Ann Med 1999;31:388-398.
4. Boolell M, Allen MJ, Ballard SA, et al. Sildenafil: An orally active type 5 cyclic GMP-specific phosphodiesterase inhibitor for the treatment of penile erectile dysfunction. Int J Impot Res 1996;8:47-52.
5. Ballard SA, Gingell CJ, Tang K, et al. Effects of sildenafil on the relaxation of human corpus cavernosum tissue in vitro and on the activities of cyclic nucleotide phosphodiesterase isozymes. J Urol 1998;159:2164-2171.
6. Moreland RB, Goldstein I, Traish A. Sildenafil, a novel inhibitor of phosphodiesterase type 5 in human corpus cavernosum smooth muscle cells. Life Sci 1998;62:309-318.
7. Beavo JA. Cyclic nucleotide phosphodiesterases: Functional implications of multiple isoforms. Physiol Rev 1995;75:725-748.
8. Wallis RM, Corbin JD, Francis SH, et al. Tissue distribution of phosphodiesterase families and the effects of sildenafil on tissue cyclic nucleotides, platelet function, and the contractile responses of trabeculae carneae and aortic rings in vitro. Am J Cardiol 1999;83(5A):3C-12C.
9. Goldstein I, Lue TF, Padma-Nathan H, et al. Oral sildenafil in the treatment of erectile dysfunction. N Engl J Med 1998;338:1397-1404.
10. Cheitlin MD, Hutter AM Jr, Brindis RG, et al. Use of sildenafil (Viagra) in patients with cardiovascular disease. Technology and practice executive committee. Circulation 1999;99:168-177.
11. Haverkamp W, Breithardt G, Camm AJ, et al. The potential for QT prolongation and pro-arrhythmia by non-antiarrhythmic drugs: Clinical and regulatory implications. Report on a Policy Conference of the European Society of Cardiology. Cardiovasc Res 2000;47:219-233.
12. Bazett HC. An analysis of the time relationships of the heart. Heart 1920;7:353-370.
13. Pye MP, Cobbe SM. Mechanism of ventricular arrhythmias in cardiac failure and hypertrophy. Cardiovasc Res 1992;26:740-750.
14. Day CP, McComb JM, Cambell RWF. QT dispersion: an indication of arrhythmia risk in patients with long QT intervals. Br Heart J 1990;63:342-344.
15. Buja G, Miorelli M, Turrini P, et al. Comparison of QT dispersion in hypertophic cardiomyopathy between patients with and without ventricular arrhythmias and sudden death. Am J Cardiol 1993;72:973-976.
16. Lorincz I, Matyus J, Zilahi Z, et al. QT dispersion in patients with end-stage renal failure and during hemodialysis. J Am Soc Nephrol 1999;10:1297-1302.
17. Tieleman RG, Crijns HJ, Wiesfeld AC, et al. Increased dispersion of refractoriness in the absence of QT prolongation in patients with mitral valve prolapse and ventricular arrhythmias. Br Heart J 1995;73:37-40.
18. c interval prolongation associated with citalopram overdose: A case report and literature review. Clin Neuropharmacol 2001;24:158-162.
19. Demolis JL, Kubitza D, Tenneze L, et al. Effect of a single oral dose of moxifloxacin (400 mg and 800 mg) on ventricular repolarization in healthy subjects. Clin Pharmacol Ther 2000;68:658-66.
20. Lenz TL, Hilleman DE. Dofetilide. A new class III antiarrhythmic agent. Pharmacotherapy. 2000;20:776-786.
21. Thomas AR, Chan LN, Bauman JL, et al. Prolongation of the QT interval related to cisapride-diltiazem interaction. Pharmacotherapy 1998;18:381-385.
22. Vorperian VR, Zhou Z, Mohammad S, et al. Torsade de pointes with an antihistamine metabolite: Potassium channel blockade with desmethylastemizole. J Am Coll Cardiol 1996;28:1556-1561.
23. Koide Y, Yotsukura M, Yoshino H, et al. Usefulness of QT dispersion immediately after exercise as an indicator of coronary stenosis independent of gender or exercise-induced ST-segment depression. Am J Cardiol 2000;86:1312-1317.
24. Musha H, So T, Hashimoto N, et al. Dynamic changes of QT dispersion as a predictor of myocardial ischemia on exercise testing in patients with angina pectoris. Jpn Heart J 1999;40:119-126.